USE OF PREDICTIVE PROBABILITIES IN PHASE II AND PHASE III CLINICAL TRIALS

DOI10.1081/BIP-100101000MaRDI QIDQ4244517zbMATH OpenOpenAlexWikidataFDO

Authors Don Johns, John S. Andersen

Publication date 5 September 1999

Published in Journal of Biopharmaceutical Statistics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1081/bip-100101000

zbMATH Keywords

beta-binomial distributioninterim analysestherapeutic equivalence

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Bayesian prediction for two-stage sequential analysis in clinical trials
• Monitoring Clinical Trials Based on Predictive Probability of Significance
• Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials
• Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials
• Sample size reestimation by Bayesian prediction

Cited in

(5)

• Predictive Hierarchic Modeling of Operational Characteristics in Clinical Trials
• Bayesian prediction for two-stage sequential analysis in clinical trials
• Uses, Abuses and Misuses of Significance Tests in the Scientific Community: Won't the Bayesian Choice be Unavoidable?
• A hybrid Bayesian-frequentist predictive design for monitoring multi-stage clinical trials
• Implementing Bayesian predictive procedures: the \(K\)-prime and \(K\)-square distributions

This page was built for publication: USE OF PREDICTIVE PROBABILITIES IN PHASE II AND PHASE III CLINICAL TRIALS

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4244517)